Under the terms of the agreement, Bloomlife will pay BioTelemetry a percentage of revenue to license their proprietary telemetry technology to commercialize a consumer oriented prenatal health sensor.
This sensor will collect and deliver a wide variety of prenatal data to expectant mothers that can be shared with their healthcare providers.
Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: “We are extremely excited to partner with Bloomlife to expand the use of our proprietary technology to the consumer-directed healthcare market.
“This partnership advances our ongoing strategic commitment to identify new markets that would benefit from the use of our technology. Bloomlife’s novel use of BioTelemetry’s platform will provide the necessary health information to positively impact pregnancy outcomes with its future developments. We are proud to partner with Bloomlife to improve the lives of expectant mothers and their families.”
Eric Dy, Chief Executive Officer of Bloom Technologies, Inc., added: “We strive to take the guesswork out of pregnancy, easing minds and providing actionable data to expectant mothers.
“We believe the combination of our expertise and BioTelemetry’s technology will help advance research aimed at the prevention of pregnancy complications. We look forward to a long and successful partnership with BioTelemetry.”
BioTelemetry, Inc., formerly known as CardioNet, Inc., is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care.
The company currently provides cardiac monitoring services, original equipment manufacturing with a primary focus on cardiac monitoring devices and centralized cardiac core laboratory services.
